glp-1 drugs and fatty liver Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic disease (NAFLD): A systematic review - Lv - 2020 - Endocrinology, Diabetes & Metabolism Current Status of Glucagon-like Peptide-1

2) Average weekly craving, average drinks per day, drinks per drinking day, number of heavy drinking days, and number of drinking vs abstinent days measured with daily self-report logs

Novo Nordisks blockbuster molecule, semaglutide, was launched for Type 2 diabetes (T2D) in 2018 as Ozempic

The Bottom Line Accessibility can make or break the success of a product or a class of products

Pharmacokinetics Half-life : ~7 days supports once-weekly dosing Peak plasma concentration : Reached in 13 days post-injection Metabolism : Proteolytic cleavage and -oxidation of fatty acid side chain Excretion : Primarily via urine and feces

Methods Scoping Review This is a scoping literature review on the extent of research on the combined use of GLP1-RAs and SGLT2is in individuals with T2D

Obesity stigma underlies much mythology